Who is sponsoring NCT00940251?

NCT00940251 is sponsored by Jyoti Clinical and Pathological Laboratory.

What drugs are being tested in NCT00940251?

Interventions in NCT00940251: Mersina.

Is NCT00940251 still recruiting?

NCT00940251 is currently completed. Last updated 14 July 2009.

Last reviewed 2009-07-14 · How we verify

NCT00940251

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs

Completed Phase 2 Last updated 14 July 2009

What this trial tests

Phase 2 trial testing Mersina in Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents in 26 participants. Completed in 1 November 2008.

Timeline

1 September 2008

Primary endpoint
1 October 2008

1 November 2008

Quick facts

Lead sponsor	Jyoti Clinical and Pathological Laboratory
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	26
Start date	1 September 2008
Primary completion	1 October 2008
Estimated completion	1 November 2008
Sites	1 location across India

Drugs / interventions tested

Mersina — full drug profile →

Conditions studied

Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents — all drugs for Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents →

Sponsor

Jyoti Clinical and Pathological Laboratory

Who can join

Adults 30 to 60, any sex, with Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

antidiabetic activity
Time frame: 3 months

Sponsor's own description

To determine the safety and efficacy of an Ayurvedic formulation, Mersina in type 2 diabetic patients with secondary failure to oral hypoglycemic agents, a randomized double blind, single centre, study of 3 months duration was carried out.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00940251 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jyoti Clinical and Pathological Laboratory
Last refreshed: 14 July 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00940251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing